Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Study to Assess the Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic Hepatitis With HCV Genotype 2 Infection

NCT04774107 is registered in ClinicalTrials.gov with PharmaEssentia as lead sponsor.

NCT NCT04774107
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04774107 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Study to Assess the Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic Hepatitis With HCV Genotype 2 Infection
Lead sponsor
PharmaEssentia
Phase
Phase 1
Overall status
Completed
Start date
November 26, 2020
Completion date
July 18, 2022
Enrollment
17 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c, chronic